EPO and periventricular leukomalacia: In contrast to the previous trial13 assessing the neuroprotective effect of early high-dose erythropoietin in the first 42 hours after birth in preterm infants born before 32 weeks, which reported less MRI brain abnormality than with placebo, the EpoRepair trial includes fewer scanned patients (100 vs 165), all with grade 2 or higher IVH, and several with subsequent complications, such as PHH and PVL.